Insilico Launches First Real-World AI Drug Discovery Benchmark
Event summary
- Insilico Medicine launched the Drug Discovery and Development (DDD) Benchmarks as a Service on July 30, 2026.
- The benchmark evaluates frontier AI and foundation models using real-world data and proprietary validated programs.
- It includes two evaluation suites: Drug Discovery Foundations with 300+ evaluations and Drug Candidate Essentials for end-to-end drug discovery assessment.
- Results can be published on a transparent public leaderboard.
The big picture
As AI models increasingly infiltrate drug discovery, Insilico's benchmark addresses a critical gap: ensuring models can perform real-world tasks beyond memorizing test data. This move could set a new standard for evaluating AI's role in accelerating drug development, potentially reshaping how pharmaceutical companies assess and adopt these technologies.
What we're watching
- Adoption Pace
- How quickly other organizations will adopt the DDD Benchmark to evaluate their AI models.
- Model Performance
- Whether the benchmark will reveal significant performance differences among leading AI models in drug discovery.
- Industry Standards
- The extent to which the DDD Benchmark becomes an industry standard for evaluating AI capabilities in pharmaceutical research.
Related topics